TransMedics Group, Inc. USDC – District of Massachusetts january 10, 2025 CLASS PERIOD: february 28, 2023 – JANUARY 10, 2025LEAD PLAINTIFF DEADLINE: april 15, 2025 Please complete the form below to contact Kaplan Fox regarding the TransMedics Group, Inc. Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Pamela MayerPMayer@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox & Kilsheimer LLP is Investigating TransMedics Group, Inc. (TMDX) for Potential Securities Law Violations Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ: TMDX) on behalf of investors that purchased or otherwise acquired TransMedics securities between February 28, 2023 and January 10, 2025 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in TransMedics and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than April 15, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. According to the complaint, on January 10, 2025, Scorpion Capital issued a report regarding TransMedics (“the Report”). The Report alleges, among other things, fraudulent billing schemes, off-label misuse of its devices, and reliance on kickbacks to drive sales. The Report also alleges that the Company may be under regulatory scrutiny by the U.S. Department of Justice, Internal Revenue Service, and state attorneys general for Medicare fraud linked to organ acquisition costs. On January 10, 2024, the price of TransMedics stock fell $3.74 per share, over 5%, to close at $68.81 per share. The stock continued to decline the following day, dropping nearly 7% to close at $64.05 on January 13, 2025. The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (i) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (ii) TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight; and (iii) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this investigation, please contact: Pamela A. MayerKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(646) 315-9003pmayer@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704lking@kaplanfox.com The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. Any information you submit will be maintained as confidential. If Kaplan Fox, in its sole discretion, believes that you might be an appropriate client, Kaplan Fox will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases. Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us e.l.f Beauty, Inc. See the Case TransMedics Group, Inc. See the Case Skyworks Solutions, Inc. See the Case Maravai LifeSciences Holdings, Inc. See the Case Ibotta, Inc. See the Case The Bancorp, Inc. See the Case Fluence Energy, Inc. See the Case Applied Therapeutics, Inc. See the Case Monolithic Power Systems, Inc. See the Case TELUS International Inc. See the Case Polestar Automotive Holding UK PLC See the Case Walgreens Boots Alliance, Inc. See the Case
